2018
DOI: 10.1016/j.clinthera.2018.06.014
|View full text |Cite
|
Sign up to set email alerts
|

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children

Abstract: Both RSV and influenza are targets for active therapeutic research, and promising candidates for both viruses are currently in clinical development.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
24
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(25 citation statements)
references
References 60 publications
0
24
0
1
Order By: Relevance
“…RSV is well known to be a leading cause of LRTI in infants and young children (Hall et al, 2009;Shi et al, 2017) but RSV also causes severe disease in other populations including older adults (Falsey et al, 2005;Shi et al, 2017), individuals with chronic lung or cardiac disease, and immunocompromised patients. Although therapeutic options are currently limited, several products are in development for treatment and prevention of RSV-AI (Nicholson and Munoz, 2018), many of which target viral fusion or genome replication.…”
Section: Fda Perspective Of Rsv Drug Developmentmentioning
confidence: 99%
“…RSV is well known to be a leading cause of LRTI in infants and young children (Hall et al, 2009;Shi et al, 2017) but RSV also causes severe disease in other populations including older adults (Falsey et al, 2005;Shi et al, 2017), individuals with chronic lung or cardiac disease, and immunocompromised patients. Although therapeutic options are currently limited, several products are in development for treatment and prevention of RSV-AI (Nicholson and Munoz, 2018), many of which target viral fusion or genome replication.…”
Section: Fda Perspective Of Rsv Drug Developmentmentioning
confidence: 99%
“…в исследовании клеточной модели моноцитов линии ТНр-1 (острый моноцитарный лейкоз) и клеток крови здоровых доноров показано, что препарат обладал эффектами, схожими с тимогеном, которые опосредовались путем стимуляции экспрессии генов эндосомальных рецепторов TLR 3, 7, 8, 9, цитоплазматических сенсоров RIG1/MDA5 и сигнальных факторов NFκB1 и MAVS [77]. предполагается наличие прямого противовирусного действия -взаимодействие с нуклеопротеином вирусов гриппа а и в с последующим нарушением репликации [75,78]. ингавирин характеризуется достаточно высоким профилем безопасности, что подтверждается данными полулетальной дозы LD50, превосходящей терапевтическую дозу более чем в 3 тыс.…”
Section: препараты с двойным механизмом действияunclassified
“…Three FDA-approved NAIs are oseltamivir, peramivir and zanamivir. [16] Wang et al . [17] performed a multicenter, retrospective study about 478 patients hospitalized with H7N9 infection during 2013–2017 in China.…”
Section: Treatmentsmentioning
confidence: 99%